Ghosh Subrata
Imperial College London, Hammersmith Hospital, Ducane Road, London W12 0NN, UK.
Expert Opin Biol Ther. 2003 Sep;3(6):995-1000. doi: 10.1517/14712598.3.6.995.
Lymphocyte infiltration into the intestinal tract in Crohn's disease is mediated by the interaction between alpha(4) integrin, expressed on lymphocytes, and its ligand mucosal vascular addressin cell-adhesion molecule-1 (MADCAM-1), expressed on the endothelial cells of the microvasculature in inflamed intestinal tract. Natalizumab, a recombinant, humanised monoclonal antibody against alpha(4) integrin was effective in Crohn's disease in a Phase II, randomised, controlled trial. The highest response rate and remission rates were 71 and 44% at 6 weeks, respectively, after two infusions of 3 mg of natalizumab administered 4 weeks apart. Natalizumab was well-tolerated in this study. The Phase III trial results are awaited.
在克罗恩病中，淋巴细胞浸润肠道是由淋巴细胞上表达的α4整合素与其配体黏膜血管地址素细胞黏附分子-1（MADCAM-1）之间的相互作用介导的，MADCAM-1在炎症肠道的微血管内皮细胞上表达。那他珠单抗是一种针对α4整合素的重组人源化单克隆抗体，在一项II期随机对照试验中对克罗恩病有效。在相隔4周输注两次3mg那他珠单抗后，6周时最高缓解率和缓解率分别为71%和44%。在该研究中那他珠单抗耐受性良好。III期试验结果有待观察。
